PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-90.13%
Revenue decline while AVXL shows 0.00% growth. Joel Greenblatt would examine competitive position erosion.
No Data
No Data available this quarter, please select a different quarter.
-148.93%
Gross profit decline while AVXL shows 0.00% growth. Joel Greenblatt would examine competitive position.
-595.65%
Margin decline while AVXL shows 0.00% expansion. Joel Greenblatt would examine competitive position.
15.04%
R&D growth above 1.5x AVXL's 4.55%. Michael Burry would check for spending discipline.
33.15%
G&A growth above 1.5x AVXL's 18.28%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.43%
Operating expenses growth above 1.5x AVXL's 7.89%. Michael Burry would check for inefficiency.
20.43%
Total costs growth above 1.5x AVXL's 7.89%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
3.01%
D&A growth less than half of AVXL's 12.59%. David Dodd would verify if efficiency is sustainable.
-24.86%
EBITDA decline while AVXL shows 0.00% growth. Joel Greenblatt would examine position.
-1164.87%
EBITDA margin decline while AVXL shows 0.00% growth. Joel Greenblatt would examine position.
-24.41%
Both companies show declining income. Martin Whitman would check industry conditions.
-1160.31%
Operating margin decline while AVXL shows 0.00% growth. Joel Greenblatt would examine position.
-17.39%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-24.71%
Both companies show declining income. Martin Whitman would check industry conditions.
-1163.35%
Pre-tax margin decline while AVXL shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-24.71%
Both companies show declining income. Martin Whitman would check industry conditions.
-1163.35%
Net margin decline while AVXL shows 0.00% growth. Joel Greenblatt would examine position.
-23.33%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-23.33%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.